読み込み中
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
前日終値
$5.35
$0.00 · 0.00%
日中の時刻はETです。市場データは遅延する場合があります。
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
日中レンジ
現在 $5.35
52週レンジ
現在 $5.35
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
43
適正価値
センチメント
53
まちまち
リスク
69
高リスク
モメンタム
39
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
日中レンジ
現在 $5.35
52週レンジ
現在 $5.35
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | 3306 USD | 4134 USD | 1.18万 USD | 1.31万 USD |
| 粗利益 | — | −3306 USD | −4134 USD | −1.18万 USD | −1.31万 USD |
| 研究開発 | 977.19万 USD | 929.01万 USD | 1409.56万 USD | 930.01万 USD | 980.51万 USD |
| 販売・一般管理 | 621.46万 USD | 560.85万 USD | 476.95万 USD | 562.12万 USD | 466.78万 USD |
| 営業費用 | 1598.66万 USD | 1489.86万 USD | 1886.1万 USD | 1492.12万 USD | 1447.28万 USD |
| 受取利息 | 15.38万 USD | 6.03万 USD | 2.77万 USD | — | 9.29 USD |
| 支払利息 | 1.52万 USD | 1.61万 USD | 1.38万 USD | 7027 USD | 9285 USD |
| 減価償却費と償却費 | 3918 USD | 3306 USD | 4134 USD | 1.18万 USD | 1.31万 USD |
| 営業利益 | −1598.66万 USD | −1490.19万 USD | −1886.51万 USD | −1493.3万 USD | −1448.59万 USD |
| 純利益 | −1585.06万 USD | −1485.78万 USD | −1885.12万 USD | −1527.41万 USD | −1449.52万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
